Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.

Leukemia · 2023 · PMC10539170 · PMID 37598282

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

modestly significantno p-value reported

However, despite this improvement, the engrafted mice eventually reached ERC (end-point of the study), in addition, the survival advantage for Jeko-1R was modestly significant.

also in 46 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.